

Kwok Kin Wong

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/633109/kwok-kin-wong-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

290
papers

39,617
citations

104
h-index

195
g-index

325
ext. papers

47,177
ext. citations

16.3
avg, IF

6.77
L-index

#	Paper	IF	Citations
290	MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer.. <i>OncImmunology</i> , 2022 , 11, 2029298	7.2	2
289	Loss of sensitizes immune checkpoint blockade in non-small cell lung cancer.. <i>Science Advances</i> , 2022 , 8, eabi9533	14.3	2
288	Cellular Origins of EGFR-Driven Lung Cancer Cells Determine Sensitivity to Therapy. <i>Advanced Science</i> , 2021 , 8, e2101999	13.6	5
287	SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	53
286	The KRAS Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 975-985	6.1	24
285	Recent advances in preclinical models for lung squamous cell carcinoma. <i>Oncogene</i> , 2021 , 40, 2817-2829	9.2	2
284	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 583-600	8.9	18
283	Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence. <i>Nature Genetics</i> , 2021 , 53, 881-894	36.3	6
282	ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer. <i>Nature Cancer</i> , 2021 , 2, 503-514	15.4	18
281	Lower Airway Dysbiosis Affects Lung Cancer Progression. <i>Cancer Discovery</i> , 2021 , 11, 293-307	24.4	34
280	Shining a light on metabolic vulnerabilities in non-small cell lung cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021 , 1875, 188462	11.2	4
279	Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 371-380	9.7	66
278	Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment. <i>Breast Cancer Research and Treatment</i> , 2021 , 185, 85-94	4.4	8
277	An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth. <i>Cancer Discovery</i> , 2021 , 11, 696-713	24.4	9
276	Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer. <i>Science Advances</i> , 2021 , 7,	14.3	13
275	Response to Cottu, Bozec, Basse, and Paoletti. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 344-345	9.7	7
274	MUC1-C integrates activation of the IFN- γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer 2021 , 9,		6

273	Mobocertinib (TAK-788): A Targeted Inhibitor of Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2021 , 11, 1672-1687	24.4	34
272	Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma. <i>Gut</i> , 2021 ,	19.2	2
271	Loss of Smad4 promotes aggressive lung cancer metastasis by de-repression of PAK3 via miRNA regulation. <i>Nature Communications</i> , 2021 , 12, 4853	17.4	5
270	Combined Inhibition of SHP2 and CXCR1/2 Promotes Anti-Tumor T Cell Response in NSCLC. <i>Cancer Discovery</i> , 2021 ,	24.4	6
269	Targeting the Atf7ip-Setdb1 Complex Augments Antitumor Immunity by Boosting Tumor Immunogenicity. <i>Cancer Immunology Research</i> , 2021 , 9, 1298-1315	12.5	1
268	Targeting Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib. <i>Cancer Research</i> , 2021 , 81, 5311-5324	10.1	7
267	A novel EGFR inhibitor suppresses survivin expression and tumor growth in human gefitinib-resistant EGFR-wild type and -T790M non-small cell lung cancer. <i>Biochemical Pharmacology</i> , 2021 , 193, 114792	6	0
266	Targeting HSPA1A in ARID2-deficient lung adenocarcinoma. <i>National Science Review</i> , 2021 , 8, nwab014	10.8	1
265	Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer.. <i>Cancer Discovery</i> , 2021 ,	24.4	4
264	PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer. <i>Nature Immunology</i> , 2020 , 21, 442-454	19.1	110
263	Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy. <i>Clinical Cancer Research</i> , 2020 , 26, 3431-3442	12.9	21
262	Epigenetic CRISPR Screens Identify as a Therapeutic Vulnerability in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2020 , 80, 3556-3567	10.1	8
261	Use of Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 2393-2403	12.9	12
260	New Approaches to SCLC Therapy: From the Laboratory to the Clinic. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 520-540	8.9	42
259	Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. <i>Cancer Cell</i> , 2020 , 37, 104-122.e12	24.3	107
258	MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. <i>Nature Communications</i> , 2020 , 11, 338	17.4	41
257	Ground-glass opacity-featured lung adenocarcinoma has no response to chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 2411-2417	4.9	1
256	Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma. <i>Journal of Clinical Investigation</i> , 2020 , 130, 612-624	15.9	12

255	CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer. <i>Cancer Cell</i> , 2020 , 37, 37-54.e9	24.3	73
254	Epigenetic CRISPR Screen Identifies as an Immunotherapeutic Target in -Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2020 , 10, 270-287	24.4	68
253	Gain-of-Function Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer. <i>Cancer Discovery</i> , 2020 , 10, 288-305	24.4	41
252	Activation of Oxidative Stress Response in Cancer Generates a Druggable Dependency on Exogenous Non-essential Amino Acids. <i>Cell Metabolism</i> , 2020 , 31, 339-350.e4	24.6	56
251	BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency. <i>Cancer Research</i> , 2020 , 80, 3841-3854	10.1	13
250	Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. <i>Cancer Cell</i> , 2019 , 36, 444-457.e7	24.3	69
249	Small-molecule targeting of brachyury transcription factor addiction in chordoma. <i>Nature Medicine</i> , 2019 , 25, 292-300	50.5	62
248	Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. <i>Cancer Discovery</i> , 2019 , 9, 926-943	24.4	110
247	Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. <i>Cell Reports</i> , 2019 , 27, 806-819.e5	10.6	25
246	Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma. <i>Nature Communications</i> , 2019 , 10, 1296	17.4	42
245	EZH2 Inhibitors: Take It EZy, It Is All About Context. <i>Cancer Discovery</i> , 2019 , 9, 472-475	24.4	7
244	Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity. <i>Nature</i> , 2019 , 566, 403-406	50.4	187
243	Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity 2019 , 7, 32		50
242	BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells. <i>Nature</i> , 2019 , 572, 676-680	50.4	55
241	Branched-Chain Amino Acid Metabolic Reprogramming Orchestrates Drug Resistance to EGFR Tyrosine Kinase Inhibitors. <i>Cell Reports</i> , 2019 , 28, 512-525.e6	10.6	32
240	The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity. <i>Cancer Immunology Research</i> , 2019 , 7, 1457-1471	12.5	53
239	A systems biology pipeline identifies regulatory networks for stem cell engineering. <i>Nature Biotechnology</i> , 2019 , 37, 810-818	44.5	14
238	Innate T Cells Mediate Antitumor Immunity by Orchestrating Immunogenic Macrophage Programming. <i>Cancer Discovery</i> , 2019 , 9, 1288-1305	24.4	13

237	CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC. <i>Cancer Research</i> , 2019 , 79, 4439-4452	10.1	23
236	The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis. <i>Genes and Development</i> , 2019 , 33, 1718-1738	12.6	29
235	Cullin5 deficiency promotes small-cell lung cancer metastasis by stabilizing integrin β . <i>Journal of Clinical Investigation</i> , 2019 , 129, 972-987	15.9	32
234	Identification and characterization of an alternative cancer-derived PD-L1 splice variant. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 407-420	7.4	31
233	Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. <i>Cancer Discovery</i> , 2018 , 8, 600-615	24.4	96
232	Prospective association between major depressive disorder and leukocyte telomere length over two years. <i>Psychoneuroendocrinology</i> , 2018 , 90, 157-164	5	26
231	Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. <i>Nature Medicine</i> , 2018 , 24, 638-646	50.5	213
230	In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E3978-E3986	11.5	45
229	ER Stress Signaling Promotes the Survival of Cancer "Persister Cells" Tolerant to EGFR Tyrosine Kinase Inhibitors. <i>Cancer Research</i> , 2018 , 78, 1044-1057	10.1	55
228	Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors. <i>Cell Chemical Biology</i> , 2018 , 25, 135-142.e5	8.2	42
227	Autophagy Sustains Pancreatic Cancer Growth through Both Cell-Autonomous and Nonautonomous Mechanisms. <i>Cancer Discovery</i> , 2018 , 8, 276-287	24.4	167
226	Noncanonical agonist PPAR δ ligands modulate the response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 561-566	11.5	32
225	Targeting Aberrations in Non-Small Cell Lung Cancer with Osimertinib. <i>Clinical Cancer Research</i> , 2018 , 24, 2594-2604	12.9	53
224	High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma. <i>Journal of Investigative Dermatology</i> , 2018 , 138, 1582-1590	4.3	33
223	The dTAG system for immediate and target-specific protein degradation. <i>Nature Chemical Biology</i> , 2018 , 14, 431-441	11.7	295
222	Profound Tissue Specificity in Proliferation Control Underlies Cancer Drivers and Aneuploidy Patterns. <i>Cell</i> , 2018 , 173, 499-514.e23	56.2	83
221	False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. <i>Clinical Cancer Research</i> , 2018 , 24, 4437-4443	14.9	210
220	Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression. <i>Cancer Discovery</i> , 2018 , 8, 59-73	24.4	67

219	Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS-Driven Mouse Model of Lung Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 4854-4864	12.9	26
218	Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. <i>Nature Medicine</i> , 2018 , 24, 1143-1150	50.5	131
217	De novo lipogenesis represents a therapeutic target in mutant Kras non-small cell lung cancer. <i>FASEB Journal</i> , 2018 , 32, fj201800204	0.9	24
216	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. <i>Nature Genetics</i> , 2018 , 50, 1271-1281	36.3	249
215	Intron retention is a source of neoepitopes in cancer. <i>Nature Biotechnology</i> , 2018 , 36, 1056-1058	44.5	114
214	BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in -Mutant Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2018 , 6, 1234-1245	12.5	53
213	Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. <i>JCI Insight</i> , 2018 , 3,	9.9	86
212	Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate. <i>JCI Insight</i> , 2018 , 3,	9.9	26
211	JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. <i>Journal of Clinical Investigation</i> , 2018 , 128, 789-804	15.9	47
210	Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. <i>Cancer Discovery</i> , 2018 , 8, 196-215	24.4	228
209	CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. <i>Cancer Discovery</i> , 2018 , 8, 216-233	24.4	308
208	Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in -mutant non-small cell lung cancer. <i>Oncotarget</i> , 2018 , 9, 31572-31589	3.3	27
207	Targeting PKC β s a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer. <i>Cancer Cell</i> , 2018 , 34, 954-969.e4	24.3	33
206	mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. <i>Nature</i> , 2018 , 561, 556-560	50.4	283
205	Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS. <i>Cancer Cell</i> , 2018 , 34, 439-452.e6	24.3	24
204	Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. <i>Nature Medicine</i> , 2018 , 24, 968-977	50.5	126
203	NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model. <i>Cancer Research</i> , 2018 , 78, 3709-3717	10.1	20
202	Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2018 , 8, 822-835	24.4	648

201	EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation. <i>Cancer Cell</i> , 2018 , 34, 69-84.e14	24.3	71
200	Inflammatory cytokines in major depressive disorder: A case-control study. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017 , 51, 23-31	2.6	43
199	CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma. <i>Nature Communications</i> , 2017 , 8, 13897	17.4	42
198	Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib. <i>European Journal of Radiology</i> , 2017 , 88, 15-20	4.7	10
197	Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. <i>Immunity</i> , 2017 , 46, 197-204	32.3	288
196	Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2017 , 67, 61-69	4.4	35
195	Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2017 , 7, 852-867	24.4	97
194	A novel in vivo model for studying conditional dual loss of BLIMP-1 and p53 in B-cells, leading to tumor transformation. <i>American Journal of Hematology</i> , 2017 , 92, E138-E145	7.1	2
193	Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1268-1279	8.9	99
192	Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2. <i>Nature Communications</i> , 2017 , 8, 14922	17.4	47
191	Synergy of WEE1 and mTOR Inhibition in Mutant -Driven Lung Cancers. <i>Clinical Cancer Research</i> , 2017 , 23, 6993-7005	12.9	17
190	Cell Division Cycle 42 plays a Cell type-Specific role in Lung Tumorigenesis. <i>Scientific Reports</i> , 2017 , 7, 10407	4.9	6
189	MUC1-C activates EZH2 expression and function in human cancer cells. <i>Scientific Reports</i> , 2017 , 7, 7481	4.9	29
188	Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma. <i>Cancer Research</i> , 2017 , 77, 5068-5076	10.1	16
187	Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. <i>Nature Medicine</i> , 2017 , 23, 1063-1071	50.5	169
186	MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer. <i>Oncotarget</i> , 2017 , 6, e1338998	7.2	28
185	Interplay between Notch1 and Notch3 promotes EMT and tumor initiation in squamous cell carcinoma. <i>Nature Communications</i> , 2017 , 8, 1758	17.4	95
184	CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer. <i>Theranostics</i> , 2017 , 7, 67-80	12.1	20

183	Comparative transcriptomes of adenocarcinomas and squamous cell carcinomas reveal molecular similarities that span classical anatomic boundaries. <i>PLoS Genetics</i> , 2017 , 13, e1006938	6	25
182	Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status. <i>Oncotarget</i> , 2017 , 8, 59008-59022	3.3	7
181	Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. <i>Cancer Immunology Research</i> , 2016 , 4, 1038-1048	12.5	54
180	LKB1 loss links serine metabolism to DNA methylation and tumorigenesis. <i>Nature</i> , 2016 , 539, 390-395	50.4	173
179	Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer. <i>Cancer Discovery</i> , 2016 , 6, 1006-21	24.4	71
178	STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. <i>Cancer Research</i> , 2016 , 76, 999-1008	10.1	297
177	Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. <i>Nature Communications</i> , 2016 , 7, 10501	17.4	846
176	Using stem cell biology to design precision medicine for non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2016 , 11, S4-S5	8.9	
175	Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas. <i>Cancer Research</i> , 2016 , 76, 1538-48	10.1	59
174	Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. <i>Cancer Cell</i> , 2016 , 29, 255-269	24.3	244
173	The impact of the MYB-NFIB fusion proto-oncogene in vivo. <i>Oncotarget</i> , 2016 , 7, 31681-8	3.3	7
172	Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer. <i>Oncotarget</i> , 2016 , 7, 3884-96	3.3	25
171	Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. <i>JCI Insight</i> , 2016 , 1, e87415	9.9	89
170	Functional genomics reveals that tumors with activating phosphoinositide 3-kinase mutations are dependent on accelerated protein turnover. <i>Genes and Development</i> , 2016 , 30, 2684-2695	12.6	7
169	Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. <i>Nature</i> , 2016 , 534, 129-32	50.4	414
168	Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation. <i>Cancer Immunology Research</i> , 2016 , 4, 520-30	12.5	57
167	Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 396-404	12.9	88
166	Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor. <i>Cancer Cell</i> , 2015 , 27, 149	24.3	2

165	Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. <i>Cancer Discovery</i> , 2015 , 5, 860-77	24.4	476
164	FBXO4 loss facilitates carcinogen induced papilloma development in mice. <i>Cancer Biology and Therapy</i> , 2015 , 16, 750-5	4.6	19
163	Telomere length and telomerase in a well-characterized sample of individuals with major depressive disorder compared to controls. <i>Psychoneuroendocrinology</i> , 2015 , 58, 9-22	5	39
162	LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-small Cell Lung Cancer Plasticity and Therapeutic Response. <i>Cancer Cell</i> , 2015 , 27, 698-711	24.3	94
161	PEPCK Coordinates the Regulation of Central Carbon Metabolism to Promote Cancer Cell Growth. <i>Molecular Cell</i> , 2015 , 60, 571-83	17.6	126
160	Development of Selective Covalent Janus Kinase 3 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2015 , 58, 6589-606	8.3	70
159	NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2382-2389	6.1	28
158	Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition. <i>Cancer Research</i> , 2015 , 75, 4372-83	10.1	83
157	Outcomes by tumor histology and KRAS mutation status after lung stereotactic body radiation therapy for early-stage non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2015 , 16, 24-32	4.9	50
156	Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. <i>Leukemia</i> , 2015 , 29, 27-37	10.7	43
155	Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2. <i>Cancer Research</i> , 2015 , 75, 3139-46	10.1	26
154	Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer. <i>Cancer Discovery</i> , 2015 , 5, 960-971	24.4	142
153	Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. <i>Cancer Immunology Research</i> , 2015 , 3, 855-63	12.5	53
152	EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to Topoll inhibitors. <i>Nature</i> , 2015 , 520, 239-42	50.4	166
151	LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment. <i>Journal of Clinical Investigation</i> , 2015 , 125, 4063-76	15.9	47
150	CCAAT/enhancer binding protein β s dispensable for development of lung adenocarcinoma. <i>PLoS ONE</i> , 2015 , 10, e0120647	3.7	2
149	Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone. <i>Oncotarget</i> , 2015 , 6, 11357-68	3.3	13
148	Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. <i>Nature Medicine</i> , 2014 , 20, 599-606	50.5	189

147	A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway. <i>Nature Cell Biology</i> , 2014 , 16, 108-17	23.4	205
146	Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. <i>Cancer Discovery</i> , 2014 , 4, 452-65	24.4	137
145	Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. <i>Clinical Cancer Research</i> , 2014 , 20, 1204-1211	12.9	49
144	The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. <i>Science</i> , 2014 , 343, 305-9	33.3	876
143	CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. <i>Cell</i> , 2014 , 159, 1126-1139	56.2	386
142	Ewing sarcoma mimicking atypical carcinoid tumor: detection of unexpected genomic alterations demonstrates the use of next generation sequencing as a diagnostic tool. <i>Cancer Genetics</i> , 2014 , 207, 335-9	2.3	16
141	Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 475-82	6.1	42
140	Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R. <i>Clinical Cancer Research</i> , 2014 , 20, 5483-95	12.9	12
139	Non-small-cell lung cancers: a heterogeneous set of diseases. <i>Nature Reviews Cancer</i> , 2014 , 14, 535-46	31.3	934
138	Neurotrophin receptor TrkB promotes lung adenocarcinoma metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 10299-304	11.5	56
137	Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells. <i>Clinical Cancer Research</i> , 2014 , 20, 5423-34	12.9	45
136	Mutant IDH inhibits HNF-4 α to block hepatocyte differentiation and promote biliary cancer. <i>Nature</i> , 2014 , 513, 110-4	50.4	288
135	Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. <i>Nature Medicine</i> , 2014 , 20, 1027-34	50.5	191
134	Ecaterin contributes to lung tumor development induced by EGFR mutations. <i>Cancer Research</i> , 2014 , 74, 5891-902	10.1	60
133	Evaluating TBK1 as a therapeutic target in cancers with activated IRF3. <i>Molecular Cancer Research</i> , 2014 , 12, 1055-66	6.6	32
132	Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers. <i>Cancer Research</i> , 2014 , 74, 3146-56	10.1	57
131	Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. <i>Cancer Cell</i> , 2014 , 25, 590-604	24.3	273
130	Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. <i>EMBO Journal</i> , 2014 , 33, 468-81	13	151

129	Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma. <i>Lung Cancer</i> , 2014 , 86, 255-61	5.9	47
128	Image-guided radiotherapy platform using single nodule conditional lung cancer mouse models. <i>Nature Communications</i> , 2014 , 5, 5870	17.4	35
127	Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma. <i>Nature Communications</i> , 2014 , 5, 3261	17.4	104
126	Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. <i>Cancer Cell</i> , 2014 , 26, 909-922	24.3	294
125	Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC. <i>Cancer Research</i> , 2014 , 74, 4676-84	10.1	29
124	Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M. <i>Cell Reports</i> , 2014 , 7, 1824-32	10.6	19
123	D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. <i>Genes and Development</i> , 2014 , 28, 479-90	12.6	54
122	Integrative genomic analysis reveals a high frequency of LKB1 genetic alteration in Chinese lung adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 254-8	8.9	22
121	SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas. <i>Journal of Clinical Investigation</i> , 2014 , 124, 1636-45	15.9	105
120	Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. <i>Journal of Clinical Investigation</i> , 2014 , 124, 5145-58	15.9	81
119	Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. <i>Journal of Clinical Investigation</i> , 2014 , 124, 5411-23	15.9	111
118	MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells. <i>Oncotarget</i> , 2014 , 5, 8893-905	3.3	48
117	Phenformin combines with selumetinib in targeting KRAS mutant non-small cell lung cancer cells with alternative LKB1 status.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2589-2589	2.2	
116	Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. <i>Cancer Research</i> , 2013 , 73, 5195-205	10.1	136
115	Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. <i>Cancer Research</i> , 2013 , 73, 2574-86	10.1	135
114	Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. <i>Cancer Research</i> , 2013 , 73, 6770-9	10.1	61
113	Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. <i>Cancer Discovery</i> , 2013 , 3, 1355-63	24.4	831
112	Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. <i>Cancer Research</i> , 2013 , 73, 834-43	10.1	153

111	The pivotal role of IKK β in the development of spontaneous lung squamous cell carcinomas. <i>Cancer Cell</i> , 2013 , 23, 527-40	24.3	85
110	Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. <i>Cancer Cell</i> , 2013 , 23, 121-8	24.3	288
109	EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. <i>Cancer Cell</i> , 2013 , 23, 677-92	24.3	547
108	Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment. <i>Frontiers in Oncology</i> , 2013 , 3, 86	5.3	57
107	Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. <i>Cancer Discovery</i> , 2013 , 3, 870-9	24.4	93
106	Integrative radiogenomic profiling of squamous cell lung cancer. <i>Cancer Research</i> , 2013 , 73, 6289-98	10.1	83
105	STOP gene Phactr4 is a tumor suppressor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, E407-14	11.5	11
104	Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 6183-92	12.9	150
103	Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants. <i>Journal of Biological Chemistry</i> , 2013 , 288, 16895-16904	5.4	5
102	A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 3068-77	12.9	192
101	A common p53 mutation (R175H) activates c-Met receptor tyrosine kinase to enhance tumor cell invasion. <i>Cancer Biology and Therapy</i> , 2013 , 14, 853-9	4.6	22
100	Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 322-8	8.9	130
99	Can mouse models of cancer reliably improve clinical trial outcome?. <i>Clinical Investigation</i> , 2013 , 3, 119-130		1
98	The LKB1 tumor suppressor as a biomarker in mouse and human tissues. <i>PLoS ONE</i> , 2013 , 8, e73449	3.7	14
97	Abstract B290: Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. 2013 ,		21
96	KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs. <i>Journal of Clinical Investigation</i> , 2013 , 123, 727-39	15.9	123
95	Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. <i>Journal of Clinical Investigation</i> , 2013 , 123, 2921-34	15.9	232
94	HIF1 β and HIF2 β independently activate SRC to promote melanoma metastases. <i>Journal of Clinical Investigation</i> , 2013 , 123, 2078-93	15.9	116

93	New cast for a new era: preclinical cancer drug development revisited. <i>Journal of Clinical Investigation</i> , 2013 , 123, 3639-45	15.9	63
92	Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer. <i>PLoS ONE</i> , 2013 , 8, e80885	3.7	20
91	Mouse models of cancer [How to optimize their predictive value in cancer drug development. <i>FASEB Journal</i> , 2013 , 27, 1088.17	0.9	
90	Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. <i>Cancer Discovery</i> , 2012 , 2, 934-47.4	21.4	212
89	Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 476-87	9.7	196
88	A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. <i>Nature</i> , 2012 , 483, 613-7	50.4	361
87	Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 8699-704	11.5	103
86	LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. <i>Cancer Cell</i> , 2012 , 21, 751-64	24.3	95
85	Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 4973-85	12.9	115
84	Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. <i>Cancer Research</i> , 2012 , 72, 3302-11	10.1	90
83	Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. <i>Cancer Prevention Research</i> , 2012 , 5, 544-52	3.2	109
82	Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 14476-81	11.5	208
81	The CRTC1-NEDD9 signaling axis mediates lung cancer progression caused by LKB1 loss. <i>Cancer Research</i> , 2012 , 72, 6502-11	10.1	39
80	Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response. <i>Cancer Research</i> , 2012 , 72, 5921-33	10.1	29
79	Abstract 1: Oncogenic extracellular domain mutations of ERBB2 in cancer 2012 ,		9
78	Temporal dissection of K-ras(G12D) mutant in vitro and in vivo using a regulatable K-ras(G12D) mouse allele. <i>PLoS ONE</i> , 2012 , 7, e37308	3.7	5
77	Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. <i>Nature Medicine</i> , 2011 , 17, 875-82	50.5	204
76	Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. <i>Cancer Discovery</i> , 2011 , 1, 78-89	24.4	389

75	MRP is a non-coding RNA essential for early murine development. <i>PLoS ONE</i> , 2011 , 6, e26270	3.7	39
74	Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. <i>Cancer Cell</i> , 2011 , 20, 400-13	24.3	199
73	A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. <i>Cancer Research</i> , 2011 , 71, 6051-60	10.1	468
72	Characterization of the cell of origin for small cell lung cancer. <i>Cell Cycle</i> , 2011 , 10, 2806-15	4.7	119
71	Lysine-specific demethylase 2B (KDM2B)-let-7-enhancer of zester homolog 2 (EZH2) pathway regulates cell cycle progression and senescence in primary cells. <i>Journal of Biological Chemistry</i> , 2011 , 286, 33061-9	5.4	92
70	Cigarette smoking increases copy number alterations in nonsmall-cell lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 16345-50	11.5	45
69	Abstract LB-410: Phase I dose escalation study of MM-121, a fully human monoclonal antibody to ErbB3, in patients with advanced solid tumors 2011 ,		3
68	A dual role for the immune response in a mouse model of inflammation-associated lung cancer. <i>Journal of Clinical Investigation</i> , 2011 , 121, 2436-46	15.9	68
67	Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. <i>Nature Medicine</i> , 2010 , 16, 219-23	50.5	465
66	Design and generation of MLPA probe sets for combined copy number and small-mutation analysis of human genes: EGFR as an example. <i>Scientific World Journal, The</i> , 2010 , 10, 2003-18	2.2	21
65	Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer. <i>Cancer Research</i> , 2010 , 70, 4709-18	10.1	57
64	An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. <i>Cancer Research</i> , 2010 , 70, 2485-94	10.1	227
63	LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 18892-7	11.5	125
62	Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. <i>Cancer Research</i> , 2010 , 70, 9827-36	10.1	164
61	NF-kappaB fans the flames of lung carcinogenesis. <i>Cancer Prevention Research</i> , 2010 , 3, 403-5	3.2	19
60	Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy. <i>DMM Disease Models and Mechanisms</i> , 2010 , 3, 181-93	4.1	91
59	Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. <i>Blood</i> , 2010 , 115, 559-69	2.2	88
58	Targeting the PI3K signaling pathway in cancer. <i>Current Opinion in Genetics and Development</i> , 2010 , 20, 87-90	4.9	441

57	A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. <i>Cell</i> , 2010 , 141, 69-80	6.2	1638
56	Primary tumor genotype is an important determinant in identification of lung cancer propagating cells. <i>Cell Stem Cell</i> , 2010 , 7, 127-33	18	120
55	Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. <i>Cancer Cell</i> , 2010 , 17, 547-59	24.3	187
54	Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. <i>Journal of Clinical Investigation</i> , 2010 , 120, 2528-36	15.9	127
53	Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 19503-8	11.5	262
52	HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 474-9	11.5	141
51	Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 18351-6	11.5	226
50	Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis. <i>Cancer Prevention Research</i> , 2009 , 2, 330-7	3.2	31
49	Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 481-9	6.1	17
48	GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. <i>Nature</i> , 2009 , 459, 1085-90	50.4	276
47	Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. <i>Nature</i> , 2009 , 462, 1070-4	50.4	766
46	SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. <i>Nature Genetics</i> , 2009 , 41, 1238-42	36.3	733
45	A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. <i>Cell</i> , 2009 , 137, 835-48	56.2	784
44	Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. <i>Journal of Clinical Investigation</i> , 2009 , 119, 1727-40	15.9	205
43	HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. <i>Journal of Clinical Investigation</i> , 2009 , 119, 2160-70	15.9	115
42	Somatic LKB1 mutations promote cervical cancer progression. <i>PLoS ONE</i> , 2009 , 4, e5137	3.7	195
41	Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. <i>Nature Medicine</i> , 2008 , 14, 1351-6	50.5	1121
40	Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2008 , 60 Suppl 2, S10-8	5.9	16

39	Differential roles of telomere attrition in type I and II endometrial carcinogenesis. <i>American Journal of Pathology</i> , 2008 , 173, 536-44	5.8	21
38	Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. <i>Cancer Research</i> , 2008 , 68, 5827-38	10.1	129
37	Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. <i>Clinical Cancer Research</i> , 2008 , 14, 6478-86	12.9	67
36	Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. <i>Cancer Research</i> , 2008 , 68, 759-66	10.1	83
35	Drug-sensitive FGFR2 mutations in endometrial carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 8713-7	11.5	292
34	The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 2070-5	11.5	1431
33	Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer. <i>Carcinogenesis</i> , 2008 , 29, 747-53	4.6	40
32	Magnetic resonance imaging of the response of a mouse model of non-small cell lung cancer to tyrosine kinase inhibitor treatment. <i>Comparative Medicine</i> , 2008 , 58, 276-81	1.6	7
31	Alu elements mediate MYB gene tandem duplication in human T-ALL. <i>Journal of Experimental Medicine</i> , 2007 , 204, 3059-66	16.6	71
30	Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. <i>Journal of Clinical Investigation</i> , 2007 , 117, 346-52	15.9	40
29	High-throughput oncogene mutation profiling in human cancer. <i>Nature Genetics</i> , 2007 , 39, 347-51	36.3	847
28	Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. <i>Nature</i> , 2007 , 447, 966-71	50.4	327
27	LKB1 modulates lung cancer differentiation and metastasis. <i>Nature</i> , 2007 , 448, 807-10	50.4	774
26	Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. <i>Cancer Cell</i> , 2007 , 12, 81-93	24.3	193
25	Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. <i>Cancer Biology and Therapy</i> , 2007 , 6, 661-7	4.6	72
24	Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. <i>Cancer Research</i> , 2007 , 67, 11867-75	10.1	128
23	PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. <i>Cancer Research</i> , 2007 , 67, 11924-32	10.1	589
22	HKI-272 in non small cell lung cancer. <i>Clinical Cancer Research</i> , 2007 , 13, s4593-6	12.9	41

21	DNA-dependent protein kinase catalytic subunit is not required for dysfunctional telomere fusion and checkpoint response in the telomerase-deficient mouse. <i>Molecular and Cellular Biology</i> , 2007 , 27, 2253-65	4.8	60
20	Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. <i>Cancer Research</i> , 2007 , 67, 4933-9	10.1	134
19	C7-04: Efficacy of BIBW 2992, a potent irreversible inhibitor of EGFR and HER2 in human NSCLC xenografts and in a transgenic mouse lung-cancer model. <i>Journal of Thoracic Oncology</i> , 2007 , 2, S380	8.9	7
18	The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. <i>Cancer Cell</i> , 2006 , 9, 485-95	24.3	389
17	EGFR targeted therapy: view from biological standpoint. <i>Cell Cycle</i> , 2006 , 5, 2072-6	4.7	27
16	Mouse models of lung cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 4396s-4402s	12.9	35
15	Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. <i>Cancer Research</i> , 2006 , 66, 6487-91	10.1	121
14	Respiratory failure due to differentiation arrest and expansion of alveolar cells following lung-specific loss of the transcription factor C/EBPalpha in mice. <i>Molecular and Cellular Biology</i> , 2006 , 26, 1109-23	4.8	56
13	Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 7817-22	11.5	229
12	Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. <i>Biological Psychiatry</i> , 2006 , 60, 432-5	7.9	391
11	Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. <i>Nature Medicine</i> , 2006 , 12, 852-5	50.5	283
10	Large Scale Copy Number Variation Upregulates the Expression of MYB in Human T-ALL.. <i>Blood</i> , 2006 , 108, 1408-1408	2.2	
9	An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. <i>Cancer Research</i> , 2005 , 65, 7096-101	10.1	231
8	High-resolution genomic profiles of human lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 9625-30	11.5	326
7	Telomere dysfunction and Atm deficiency compromises organ homeostasis and accelerates ageing. <i>Nature</i> , 2003 , 421, 643-8	50.4	330
6	Walking the telomere plank into cancer. <i>Journal of the National Cancer Institute</i> , 2003 , 95, 1184-6	9.7	12
5	The age of cancer: telomeres, checkpoints, and longevity. <i>Journal of Clinical Investigation</i> , 2003 , 111, S9-14	15.9	22
4	Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation. <i>Nature Genetics</i> , 2000 , 26, 85-8	36.3	267

- 3 Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. *Science*, **1997**, 276, 596-9 33.3 353
- 2 TFE3 contains two activation domains, one acidic and the other proline-rich, that synergistically activate transcription. *Nucleic Acids Research*, **1995**, 23, 3865-71 20.1 42
- 1 Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer 1